JP2008540346A - Pharmaceutical formulation of oxcarbazepine and preparation method thereof - Google Patents

Abstract

  The present invention provides a pharmaceutical composition comprising oxcarbazepine and at least one pharmaceutical excipient, wherein the oxcarbazepine in the composition has a broad particle size distribution. . The broad particle size distribution of oxcarbazepine in the pharmaceutical composition is preferably a multimodal oxcarbazepine particle size distribution, preferably with an improved oxcarbazepine dissolution rate.

Description

  No. 60 / 764,134 (filed Jan. 31, 2006), No. 60 / 860,333 (filed Nov. 20, 2006), and No. 60 / 897,361. Filed Jan. 24, 2007) (named “Pharmaceutical formulations of oxcarbazepine and methods for its preparation”), and US patent application Ser. No. 11 / 350,606 (2006). Claim the benefit of (filed on Feb. 8). The contents of these applications are incorporated herein by reference.

  The present invention relates to pharmaceutical formulations. More specifically, the present invention relates to a formulation comprising oxcarbazepine and a method for preparing this pharmaceutical formulation. Since both oxcarbazepine and carbamazepine are very similar such as low elution, the present invention is similarly applied to a pharmaceutical preparation comprising carbamazepine.

で表わされる、オキシカルバゼピン（１０−オキソ−１０，１１−ジヒドロ−５Ｈ−ジベンズ［ｂ，ｆ］アゼピン−５−カルボキサミド）は、有益な治療効果を示し、中枢神経系の抑制剤として機能する。現在はTRILEPTAL（登録商標）として、癲癇の治療用に市販されている。TRILEPTAL（登録商標）の処方情報によれば、オキシカルバゼピンの薬理学的効果は、主としてオキシカルバゼピンの１０−ヒドロキシ代謝産物を通じて発揮される。生体外での研究によれば、この代謝産物が電位感受性ナトリウムチャネルを遮断することにより、過興奮下の神経細胞膜を安定化し、ニューロン発射の反復を抑え、シナプス刺激の伝播を縮小することが明らかになっている。これらの作用は、脳内に広がる発作の予防に重要であると考えられている。米国特許第５，６５８，９００号（当該文献は引用により本明細書に組み込まれる）には更に、オキシカルバゼピンをパーキンソン病の治療に用いることが記載されている。 The following general formula

Oxcarbazepine (10-oxo-10,11-dihydro-5H-dibenz [b, f] azepine-5-carboxamide) represented by the formula shows a beneficial therapeutic effect and functions as an inhibitor of the central nervous system To do. Currently, it is marketed as TRILEPTAL® for the treatment of hemorrhoids. According to TRILEPTAL® prescribing information, the pharmacological effects of oxcarbazepine are exerted primarily through the 10-hydroxy metabolite of oxcarbazepine. In vitro studies show that this metabolite blocks voltage-sensitive sodium channels, which stabilizes hyperexcited nerve cell membranes, suppresses repeated neuronal firing, and reduces the transmission of synaptic stimuli It has become. These effects are thought to be important in preventing seizures that spread in the brain. US Pat. No. 5,658,900 (which is incorporated herein by reference) further describes the use of oxcarbazepine for the treatment of Parkinson's disease.

  Oxcarbazepine, an antiepileptic drug, is a white to yellowish crystalline powder that is substantially insoluble in water. There is a need to increase the dissolution rate and bioavailability of oxcarbazepine preparations. For drugs with poor dissolution properties, it has been known in the art for some time to use small particles of these drugs and to use a narrow particle size distribution in order to increase dissolution and bioavailability. This is considered to be the general practice above. Based on this idea, Schlutermann (US patent application 2003/0190361) describes a formulation comprising oxcarbazepine with a fine particle size and a narrow particle size distribution. The particles are characterized by a median particle size of approximately 2 to 12 microns and / or a maximum residue of up to 5% remaining on a 40 micron sieve. Schlutermann also describes a film-coated tablet comprising oxcarbazepine particles having the same properties. EP 0 646 374 further describes a color stable oxcarbazepine formulation, each coated with two layers containing a white pigment.

  A general method for pulverizing a drug is a method using a jet mill. A jet mill uses compressed air to produce finely divided particles from large dry particles. According to the jet mill configuration, the powdered particles are discharged from the milling chamber and collected in a collection container. Fine particles of waste are also produced during the treatment, but this is collected in a filter bag. Since such a pulverization process is a time-consuming process, high costs are required not only for its investment but also for operation. In addition, these treatments result in a considerable amount of drug loss during grinding. Furthermore, during milling with an air jet mill, fine powder of active pharmaceutical ingredient (API) is generated with the treatment, so that safety must be taken into consideration. In the case of a pharmaceutical composition comprising oxcarbazepine, these concerns are more serious because the recommended daily dose is relatively large, 1200 mg / day.

  Furthermore, Sehgal et al. (WO / 2002/094744) describe a method of increasing the dissolution rate of oxcarbazepine by adding a wetting agent to the formulation. By adding such a wetting agent to the oxcarbazepine formulation, the dissolution rate in vitro is improved.

  According to a preferred embodiment, the present invention prepares an oxcarbazepine formulation that has a sufficiently high dissolution rate and good bioavailability and is a bioequivalent of the commercial agent TRILEPTAL® Provide a way to do it.

  The present invention relates to a pharmaceutical composition comprising a) oxcarbazepine and b) at least one pharmaceutical excipient, wherein the oxcarbazepine in the composition has a broad particle size distribution. A composition is provided. The broad particle size distribution may comprise a multimodal oxcarbazepine particle size distribution.

Further, a method for preparing the pharmaceutical composition of the present invention, comprising:
a) preparing an oxcarbazepine having a broad particle size distribution;
b) providing at least one excipient; and
c) A method is provided comprising the step of combining the oxcarbazepine with the at least one excipient.

A method for preparing a granular composition comprising oxcarbazepine having a broad particle size distribution,
a) preparing an oxcarbazepine having a broad particle size distribution, optionally comprising two or more oxcarbazepine populations having different particle size distributions;
b) providing at least one excipient;
c) forming at least one particulate comprising at least one of the oxcarbazepine population, and
d) Step comprising mixing the granulated oxcarbazepine with the remainder of the ungranulated oxcarbazepine and one or more excipients to form a final granular admixture. A method is provided.

When preparing a tablet from the granular composition, the method further comprises:
e) optionally mixing the final granular admixture with one or more excipients to form a tableting mixture;
f) a step of pressing either the tableting mixture or the final granular blend into a tablet and, optionally,
g) comprising the step of coating the tablet.

  The present invention also provides a pharmaceutical composition comprising a) spray granulated oxcarbazepine and b) at least one pharmaceutical excipient.

  According to another aspect, the present invention provides a pharmaceutical composition comprising a) oxcarbazepine having a broad particle size distribution and b) at least one pharmaceutical excipient. Here, optionally, the oxcarbazepine in the composition comprises at least two oxcarbazepine particle populations of different particle sizes, and at least one of these populations is spray granulated oxcarbazepine. Zepin may be included.

  A pharmaceutical composition further comprising a) an oxcarbazepine having a broad particle size distribution, b) a hydrophilic polymer, preferably hydroxypropylmethylcellulose (hypromellose, HPMC), and c) at least one pharmaceutical excipient. And wherein the weight ratio of hydrophilic polymer to oxcarbazepine in the composition is from about 1: 3 to about 1:25. The broad particle size distribution of oxcarbazepine is preferably a multimodal particle size distribution.

  According to another aspect, a pharmaceutical composition comprising a) an oxcarbazepine having a broad particle size distribution and b) at least one pharmaceutical excipient, wherein the biology of TRILEPTAL® A pharmaceutical composition is provided that is a functional equivalent. The broad particle size distribution of oxcarbazepine is preferably a multimodal particle size distribution.

  According to another aspect, a pharmaceutical composition comprising a) an oxcarbazepine having a broad particle size distribution, and b) at least one pharmaceutical excipient, wherein the disintegration time is less than about 30 minutes. Certain pharmaceutical compositions are provided. The broad particle size distribution of oxcarbazepine is preferably a multimodal particle size distribution.

And a method of preparing a granular composition comprising at least two oxcarbazepine populations of different particle sizes, wherein the at least one oxcarbazepine particle population is spray granulated,
a) preparing an oxcarbazepine comprising two or more oxcarbazepine populations having different particle size distributions;
b) mixing at least one oxcarbazepine particle population with one or more excipients to form at least one spray granulate; and
c) mixing said at least one particle size spray granulated oxcarbazepine population with a remaining particle size non-spray granulated oxcarbazepine particle population, from the total amount of oxcarbazepine in said composition There is provided a method comprising the step of forming an oxcarbazepine mixture.

When preparing a tablet from the granular composition, the method further comprises:
d) mixing the oxcarbazepine mixture with one or more excipients to form a final granulate;
e) mixing the final granulate with one or more excipients to form a tableting mixture;
f) press-molding the tableting mixture into tablets and optionally,
g) comprising at least one of the steps of coating the tablet.

And a method of preparing a granular composition comprising at least two oxcarbazepine populations of different particle sizes, wherein the at least one oxcarbazepine particle population is spray granulated,
a) preparing an oxcarbazepine comprising two or more oxcarbazepine populations having different particle size distributions; and
b) spraying at least one oxcarbazepine particle population onto a mixture of one or more excipients and the remaining oxcarbazepine population to form at least one spray granulation A method comprising the steps is provided.

When preparing a tablet from the granular composition, the method further comprises:
c) optionally mixing the final granulate with one or more excipients to form a tableting mixture;
d) press-molding the tableting mixture into tablets, and optionally,
e) comprising at least one of the steps of coating the tablet.

Furthermore, a method for preparing a granular composition comprising at least two oxcarbazepine populations having different particle sizes, wherein at least two oxcarbazepine particle populations are spray granulated,
a) preparing an oxcarbazepine comprising two or more oxcarbazepine populations having different particle size distributions;
b) separately spraying at least two oxcarbazepine particle populations with one or more excipients to form at least two spray granulates; and
c) A method is provided comprising the step of mixing the oxycarbazepine collective spray granulate of the at least two oxcarbazepine particle sizes.

When preparing a tablet from the granular composition, the method further comprises:
d) optionally mixing the oxcarbazepine mixture with one or more excipients to form a final granulate;
e) mixing the final granulate with one or more excipients to form a tableting mixture;
f) press-molding the tableting mixture into tablets and optionally,
g) comprising at least one of the steps of coating the tablet.

A method for preparing a granular composition comprising oxcarbazepine having a broad particle size distribution,
a) providing an oxcarbazepine comprising a plurality of broad particle size distributions; and
b) A method is provided that comprises spraying the oxcarbazepine particles with one or more excipients to form a spray granulation.

When preparing a tablet from the granular composition, the method further comprises:
c) optionally mixing the granulate with one or more excipients to form a tableting mixture;
d) a method of pressing the tableting mixture into a tablet and optionally,
e) comprising at least one of the steps of coating the tablet.

According to another aspect, the present invention provides a pharmaceutical composition comprising oxcarbazepine having a broad particle size distribution comprising:
a) About 35% or less of the total amount of oxcarbazepine elutes from the composition after 35 minutes of measurement in the dissolution apparatus,
b) After 50 minutes of measurement in the dissolution apparatus, about 30% to about 50%, preferably about 40% of the total amount of oxcarbazepine is eluted from the composition;
c) After a measurement of 60 minutes in the dissolution apparatus, about 30% to about 50% of the total amount of oxcarbazepine is eluted from the composition, and the dissolution apparatus system has an dissolution profile that simulates the gastrointestinal environment. Pharmaceutical compositions are also provided.

  According to another aspect, the present invention provides a method for treating a patient suffering from epileptic seizures or Parkinson's disease or neuropathic pain in a pharmaceutical composition comprising a multimodal oxcarbazepine particle size distribution. A method is provided comprising the step of administering a therapeutically effective amount of oxcarbazepine.

  According to another embodiment of the present invention, carbazepine was used instead of oxcarbazepine in the pharmaceutical composition according to any of the above embodiments, the method of preparing the pharmaceutical composition, and the method of treatment. Things are provided.

  As used herein, the term “broad particle size distribution” means that the difference between the d (0.5) value and the d (0.95) value is greater than 38 microns, and d (0.5 ) Means a specific particle size distribution with a value of 35 microns or less. These d values may be determined by laser diffraction, sieving, or other methods known in the art. For example, the value of d (0.95) is estimated from the sieve size that allows 95% or less of the particles to pass. As used herein, “d (0.5)” (sometimes referred to as “d (v, 0.5)” or volume median diameter) refers to d ( 0.5) represents the particle size (diameter) such that the cumulative volume of all particles below the value is equal to 50% of the total volume of all particles in the population.

  According to one embodiment, the broad particle size distribution of oxcarbazepine has a d (0.5) value in the range of 12 to 35 μm, preferably in the range of 13 to 30 μm, more preferably in the range of 14 to 25 μm. It may be characterized by that. According to another embodiment, d (0.5) is in the range of 0.01 μ to 2.0 μ (more preferably in the range of 0.2 to 1.9 μ, most preferably 0.4 to 1.5 μ. Range). According to another embodiment, d (0.5) is in the range of 2-12μ.

  Regardless of the d (0.5) value, d (0.95) is preferably greater than 40μ. For example, if the population is sieved using a 40μ sieve, the residue on the sieve is greater than 5%.

  The terms “multimodal particle size distribution” and “multimodal oxcarbazepine particle size distribution” are two or more types when the oxcarbazepine particle size is graphed on a volume or weight basis. It should be understood that it means oxcarbazepine characterized by exhibiting a peak particle size of For example, a multimodal particle size distribution of oxcarbazepine is prepared by mixing at least two oxcarbazepine populations characterized by different particle size distributions. The multimodal particle size distribution of the present invention is preferably a bi-modal particle size distribution. In the bimodal particle size distribution, the difference between the two modes of the oxcarbazepine particle population is preferably about 12 microns or more, preferably about 13 microns or more. The particle size distribution described in the present invention can be determined by various conventional analysis methods. Examples include laser light scattering, laser diffraction, sedimentation method, pulse method, electrical zone sensing, sieve analysis, and optical microscopy (usually in combination with image analysis). The evaluation of the particle size distribution for a multimodal particle size distribution prepared by mixing at least two oxcarbazepine populations is to prepare a mixture of a plurality of oxcarbazepine particle size populations at an appropriate ratio. Can be carried out by analyzing by laser diffraction. Another technique for evaluating multimodal particle size distribution (PSD) is to numerically calculate d (0.1), d (0.5), and d (0.9). A method is mentioned. This is done by calculating the PSD weighted average (mean, average) for each oxcarbazepine population. See, for example, Table 1.

  As used herein, the term “large drug particles” refers to a population having a d (0.5) of about 12 microns or more, preferably about 13 microns or more. The large oxcarbazepine particle population is selected from the group consisting of an oxcarbazepine particle population with d (0.5) of 13 microns or greater, an unmilled particle population, particles that do not pass through a 40 micron sieve, and mixtures thereof. Preferably characterized as a population. The large oxcarbazepine particle population is characterized as a population having a d (0.5) oxcarbazepine particle size of about 13 microns or greater and comprises more than about 5% of particles that do not pass through a 40 micron sieve. Is preferred. That is, when a large oxcarbazepine particle population is sieved using a 40 micron sieve, the residue on the sieve is greater than 5% or d (0.95) is greater than 40 microns. In such a large oxcarbazepine particle population, the amount of residue on the 40 micron sieve is preferably greater than about 25% and more preferably greater than about 50%. Accordingly, d (0.5) of oxcarbazepine in the large oxcarbazepine particle population is preferably 30 microns or more, more preferably 45 microns or more, and even more preferably 55 microns or more. The large oxcarbazepine particle population may also be characterized in that the d (0.5) value is in the range of about 12 to 120 microns, preferably in the range of about 60 to 90 microns. The term “unground particles” refers to particles obtained by synthesis of oxcarbazepine (active pharmaceutical ingredient (API)) that have not yet been ground or are minimally ground. It represents something that has only been done. The unmilled oxcarbazepine particles have a d (0.5) greater than 13 microns. According to one example, the unmilled particles are characterized by their d (0.1), d (0.5), and d (0.9) being about 21, 71, and 248 microns, respectively.

  On the other hand, the term “small drug particles” as used herein usually has a d (0.5) value of less than 6 microns, preferably less than 3 microns, more preferably less than 2 microns. Means a drug particle population. When the same population is sieved using a 40 μm sieve, the residue on the sieve is preferably less than 5%, or d (0.95) is preferably less than 40 microns.

  The term “sprayed granulated oxcarbazepine” as used herein refers to a granulated oxcarbazepine particle population that is granulated by spraying an oxcarbazepine dispersion onto a powder carrier. Point to.

  An important point in the formulation of oxcarbazepine dosage forms for medical use is that the dissolution rate of oxcarbazepine, which is a pharmaceutical active ingredient with poor dissolution properties, from the pharmaceutical composition is sufficient. According to the present invention, an oxcarbazepine comprising a broad particle size distribution having an elution rate comparable to that of TRILEPTAL® bioequivalent preparation (TRILEPTAL® bioequivalent composition A). Can be achieved with a formulation having A preferred embodiment of the present invention is a pharmaceutical composition comprising oxcarbazepine, preferably having a desired dissolution rate and bioavailability, wherein the formation of fines during the grinding process is low and / or Including compositions obtained using safer methods with reduced milling costs and loss of active pharmaceutical ingredients. According to one embodiment of the present invention, a pharmaceutical composition comprising a) oxcarbazepine and b) at least one pharmaceutical excipient, wherein the oxcarbazepine in the composition is broad. A composition having a uniform particle size distribution is provided. This broad particle size distribution may be a multimodal oxcarbazepine particle size distribution.

  The oxcarbazepine pharmaceutical composition of the present invention is characterized in that its particle size distribution is broad. The particle size distribution can be determined by various conventional methods. Examples include laser light scattering, laser diffraction, sedimentation method, pulse method, electrical zone sensing, sieve analysis, and optical microscopy (usually in combination with image analysis).

  The multimodal oxcarbazepine particle size distribution in the pharmaceutical composition preferably contains at least two particle populations. Each of these populations has a different median particle size (or volume median diameter) and a distinct particle size distribution.

  According to a preferred embodiment of the present invention, the pharmaceutical composition comprises two or more oxcarbazepine particle populations, at least one of which is a large oxcarbazepine particle population. The large oxcarbazepine particle population is selected from the group consisting of an oxcarbazepine particle population with d (0.5) of 13 microns or greater, an unmilled particle population, particles that do not pass through a 40 micron sieve, and mixtures thereof. Characterized as a group.

  One embodiment of the present invention comprises a pharmaceutical of the present invention comprising large oxcarbazepine particles in an amount from about 6% to about 49% by weight relative to the total amount of oxcarbazepine in the pharmaceutical composition. Includes the composition. Further, in this embodiment, the pharmaceutical composition of the invention comprises at least one small oxcarbazepine particle population, wherein the oxcarbazepine d (0.5) is less than about 6 microns, preferably Less than about 3 microns, most preferably less than 2 microns. Such pharmaceutical compositions preferably comprise small oxcarbazepine particles in an amount from about 94% to about 60% by weight, based on the total amount of oxcarbazepine in the pharmaceutical composition. The content of the small oxcarbazepine particles in the multimodal pharmaceutical composition is preferably adjusted according to the content of the large oxcarbazepine particles. That is, according to one preferred embodiment, the pharmaceutical composition comprises large oxcarbazepine particles in an amount from about 6% to about 40% by weight relative to the total amount of oxcarbazepine in the pharmaceutical composition. And comprises small oxcarbazepine particles in an amount from about 94% to about 60% by weight. Among these, the pharmaceutical composition has a large oxcarbazepine particle in the range of about 10 wt% to about 35 wt%, preferably about 10 wt%, about 20 wt%, based on the total amount of oxcarbazepine particles, And small oxcarbazepine particles in the range of about 90% to about 65% by weight, preferably about 90%, about 80%, and about 65%. More preferably, it comprises an amount selected from weight percent.

  Another embodiment of the pharmaceutical composition of the present invention comprises large oxcarbazepine particles in an amount from about 95% to about 51% by weight relative to the total amount of oxcarbazepine in the pharmaceutical composition. . Furthermore, the pharmaceutical composition of this embodiment of the invention comprises at least one small oxcarbazepine particle population, wherein d (0.5) is less than about 6 microns, preferably less than about 3 microns. Most preferably less than 2 microns. Further, such pharmaceutical compositions comprise small oxcarbazepine particles in an amount from about 5% to about 49% by weight. The content of the small oxcarbazepine particles in the pharmaceutical composition is preferably adjusted according to the content of the large oxcarbazepine particles. That is, according to one preferred embodiment, the pharmaceutical composition comprises from about 90% to about 60% by weight of large oxcarbazepine particles relative to the total amount of oxcarbazepine in the pharmaceutical composition. And comprises small oxcarbazepine particles in an amount from about 10% to about 40% by weight. In particular, the pharmaceutical composition comprises large oxcarbazepine particles in an amount of about 85% to about 65% by weight, and small oxcarbazepine particles with respect to the total amount of oxcarbazepine particles. More preferably, it comprises in an amount from 15% to about 35% by weight.

  According to another embodiment of the invention, the d (0.5) of the oxcarbazepine particle population is 2 microns or less and the minimum residue on a 40 micron sieve is greater than 5%. Alternatively, according to another embodiment of the present invention, the d (0.5) of the oxcarbazepine particle population is 2 to 12 microns and the minimum residue on a 40 micron sieve is greater than 5%. Further, according to another embodiment of the present invention, d (0.5) of oxcarbazepine is greater than 13 microns and the minimum residue on a 40 micron sieve is greater than 5%.

  According to another embodiment of the present invention, there is provided a pharmaceutical composition comprising a) oxcarbazepine and b) at least one pharmaceutical excipient comprising the oxcarbazepine in said composition. Compositions are provided characterized by a particle size distribution with a d (0.5) value in the range of 13 to 40 microns, with a residue on the 40 micron sieve greater than 5%. The oxcarbazepine may be derived from a single particle population.

  Furthermore, according to another embodiment of the invention, the pharmaceutical composition comprises spray granulated oxcarbazepine. In this embodiment of the invention, such a pharmaceutical composition comprises a) oxcarbazepine and b) at least one pharmaceutical excipient, wherein the oxcarbazepine has a broad particle size distribution. preferable. The broad particle size distribution of the oxcarbazepine particles may be a multimodal particle size distribution. As stated, such a multimodal particle size distribution comprises two or more oxcarbazepine particle populations having distinct particle size distributions. In the pharmaceutical composition of the present invention comprising spray-granulated oxcarbazepine, one or more oxcarbazepine particle populations having different particle size distributions are spray-granulated.

  According to another embodiment of the present invention, there is provided a pharmaceutical composition comprising a) an oxcarbazepine having a broad particle size distribution, b) a hydrophilic polymer, and c) at least one pharmaceutical excipient. A composition is provided wherein the weight ratio of hydrophilic polymer to oxcarbazepine in the composition ranges from about 1: 3 to about 1:25. This hydrophilic polymer is preferably hydroxypropyl methylcellulose (hypromellose, HPMC). The bioavailability of oral tablets can be affected by disintegration and dissolution. To reduce the disintegration time of the oxcarbazepine formulation, a defined amount of hydrophilic polymer was used when spraying small oxcarbazepine onto large oxcarbazepine particles in the spray granulation process. The ratio of hydrophilic polymer to oxcarbazepine is preferably in the range of about 1: 5 to about 1:22, more preferably in the range of about 1: 9 to about 1:20. The total amount of hydrophilic polymer in the pharmaceutical composition of the present invention is expressed as being in the range of about 120 mg or less, preferably about 20 mg to about 120 mg, more preferably about 20 mg to about 50 mg, most preferably about 30 mg to 45 mg. You can also Among them, the total amount of the hydrophilic polymer in the pharmaceutical composition of the present invention is preferably about 15% by weight or less, more preferably about 1% by weight to about 15% by weight with respect to the composition. More preferably from about 2% to about 15% by weight relative to the composition, even more preferably from about 2% to about 12% by weight relative to the composition, even more preferably relative to the composition. About 2.5% to about 10% by weight, most preferably about 2.5% to about 5% by weight of the composition. According to the most preferred embodiment, the total amount of hydrophilic polymer in the pharmaceutical composition ranges from about 2% to about 4% by weight relative to the composition. The broad particle size distribution of oxcarbazepine is preferably a multimodal particle size distribution. The oxcarbazepine of this embodiment of the invention preferably comprises at least one small particle population. This small oxcarbazepine particle population may be formed by spray granulation when preparing the pharmaceutical composition of the present invention. According to a preferred embodiment, at least one small oxcarbazepine particle population is spray granulated. The ratio of the amount of hydrophilic polymer to the amount of small oxcarbazepine particles in such spray granulations is from about 1: 3 to about 1:20, preferably from about 1: 5 to about 1:18, and more. Preferably, the range is from about 1: 9 to about 1:17.

  Oxcarbazepine pharmaceutical compositions comprising a broad particle size distribution according to the present invention may further comprise excipients such as tablets and capsule fillers and diluents (eg microcrystalline cellulose, lactose, starch and tribasic). Calcium phosphate), disintegrants (eg, starch, croscarmellose sodium, and sodium starch glycolate), binders (eg, starch, hydroxypropyl methylcellulose, and povidone), glidants (eg, colloidal silicon dioxide), Lubricants (eg, magnesium stearate, magnesium lauryl sulfate, and sodium stearyl fumarate), and surfactants and wetting agents (eg, sodium lauryl sulfate, polysorbate, and poloxamer) may be included.

  More specifically, diluents and fillers suitable for use in the pharmaceutical compositions of the present invention include microcrystalline cellulose (eg Avicel®), ultrafine cellulose, lactose, starch, pre-gelatinization ( pregelatinized) starch, calcium carbonate, calcium sulfate, sugar, dextrates, dextrin, dextrose, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, kaolin, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, potassium chloride, Examples include powdered cellulose, sodium chloride, sorbitol, and talc.

  Further, suitable surfactants for use in the pharmaceutical composition of the present invention include poloxamer, polyethylene glycol, polysorbate, sodium lauryl sulfate, polyethoxylated castor oil, and hydroxylated castor oil.

  When the solid pharmaceutical composition is compacted and formed into a dosage form such as a tablet, the solid pharmaceutical composition may contain an excipient. Excipient functions include functions that help the active ingredient and other excipients bind together after compression. Binders for solid pharmaceutical compositions include acacia, alginic acid, carbomers (eg carbopol), sodium carboxymethylcellulose, dextrin, ethylcellulose, gelatin, guar gum, hydroxyethylcellulose, hydroxypropylcellulose (eg Klucel®), Hydroxypropyl methylcellulose (eg Methocel®), liquid glucose, maltodextrin, methylcellulose, polymethacrylate, povidone (eg Povidone PVP K-30, Kollidon, Plasdone®), pre-gelatinized starch, sodium alginate, and Starch.

  In addition, when compacting a solid pharmaceutical composition, a disintegrant may be added to the composition. Disintegrants include croscarmellose sodium (eg Ac Di Sol (registered trademark), Primellose (registered trademark)), crospovidone (eg Kollidon (registered trademark), Polyplasdone (registered trademark)), microcrystalline cellulose, polacrilin potassium (Polacrilin potassium), powdered cellulose, starch before gelatinization, sodium starch glycolate (eg, Explotab®, Primoljel®), and starch.

  If the solid composition is not compacted, a glidant may be added to improve its flowability and improve dosing accuracy. Excipients that can function as glidants include colloidal silicon dioxide, magnesium trisilicate, powdered cellulose, and talc.

  A lubricant may be added to the composition to reduce the tackiness of the composition and / or to facilitate the discharge of the product from, for example, a dye. Lubricants include magnesium stearate, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, mineral oil, polyethylene glycol, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc , And zinc stearate.

  Other excipients that may be incorporated into the formulation include preservatives, antioxidants, or any other excipients commonly used in the pharmaceutical industry.

  Solid compositions of the present invention include powders, granules, aggregates, and compacted compositions. Dosage includes dosages suitable for oral, buccal and rectal administration. Although the optimum dosage in an individual case will depend on the nature and severity of the condition being treated, the most preferred route in the present invention is oral. It is convenient to provide the dosage as a unit dosage form, which can be prepared using any of the well-known methods in the pharmaceutical art.

  The present invention also discloses a method for producing an oxcarbazepine pharmaceutical composition having a broad particle size distribution. For example, one of the methods comprises a first step of mixing large oxcarbazepine particles with small oxcarbazepine particles. This mixing may be performed before granulation or may be performed at the time of granulation. Alternatively, at least a part of the large-sized oxcarbazepine particles, such as at least one large oxcarbazepine particle population, and at least a part of the small-sized oxcarbazepine particles, such as at least one small oxcarbazepine particle. The Zepin particle population is granulated separately, and the formed granule is mixed. Subsequently, this mixture may be mixed with further excipients and pressed to form tablets.

  According to a preferred embodiment, the method comprises the steps of milling a portion of the total amount of oxcarbazepine and optionally further de-agglomerating to form small drug particles. The remaining oxcarbazepine is preferably used for forming a large drug particle population as it is without being milled. Alternatively, only a small amount of milling is applied to the remainder of the oxcarbazepine to form large drug particles of the multimodal pharmaceutical composition of the present invention. This slightly milled oxcarbazepine residue retains a large particle size distribution. Various known methods can be used for milling and crushing the oxcarbazepine particles. For example, a jet mill, an impact mill, a ball mill, a vibration mill, a mortar mill, or a pin mill can be used for milling unground oxcarbazepine. Among these, oxycarbazepine is dispersed in the form of a dispersion, and milling using a crusher such as a rotor stirrer or high-pressure crusher such as microfluidizer (registered trademark) can produce a high yield of milled oxcarbazepine. Is preferable. The reduction of the oxcarbazepine particle size by such wet milling is preferably performed in the presence of a hydrophilic polymer or a stabilizer. Preferable examples of the hydrophilic polymer or the stabilizer include hypromellose (hydroxypropyl methyl cellulose: HPMC) such as Pharmacoat (registered trademark).

  It is preferred to produce a compacted solid dosage form by the method of the present invention. Well-known methods for producing such dosage forms are (i) direct compression, (ii) dry granulation, and (iii) wet granulation. Two types of wet granulation methods are well known. A homogeneous dry granulate is obtained by preparing the wet granulate using a mixer and subsequently drying the resulting wet granulate. According to another method, wet granules are prepared by spray granulation. In the fluidized bed spray granulation method, particles and particulates are generated in the fluidized bed by spraying a liquid onto the fluidized particles. That is, in such a method, the material is flowed into a fluid bed dryer and the solution is subsequently sprayed from a nozzle.

  The pharmaceutical composition of the present invention can be in any dosage form. For example, it can be set as the compression granule of shapes, such as a tablet. Moreover, the non-compressed granular material and powder mixture obtained in the step before compression in the method of the present invention can be provided in a simple dosage form such as a capsule or a sachet. Accordingly, the dosage forms of the pharmaceutical composition of the present invention include solid dosage forms such as tablets, powders, capsules, sachets, troches, and losenes. The dosage form of the present invention also includes a capsule containing the above composition, preferably a powdered or granulated solid composition of the present invention in a hard shell or soft shell. The shell can be formed from gelatin or the like. Optionally, a plasticizer such as glycerin or sorbitol, an opacifier or a colorant may be included.

  The process for making this pharmaceutical composition comprising a broad particle size distribution of oxcarbazepine comprises the step of spray granulating at least one oxcarbazepine particle population from either small drug particles or large drug particles. Preferably it comprises. According to another preferred embodiment of the preparation method, the method comprises the step of spray granulating together the small drug particle population and the large drug particle population. According to the latter embodiment, by using a pharmaceutical composition comprising spray granulated oxcarbazepine, the pulverization cost is reduced, the safety is improved, and the loss of the active pharmaceutical ingredient is suppressed. Elution rate and bioavailability can be achieved. The spray granulated particles are described in various documents. An example is the website of Glatt, a spray granulator manufacturer. The spray granulated oxcarbazepine is preferably a product obtained by spraying a dispersion of oxcarbazepine particles onto air flow excipient particles.

  According to one embodiment, the sprayed oxcarbazepine dispersion comprises relatively large oxcarbazepine particles. These relatively large particles are synthetically obtained oxcarbazepine particles that have not been milled, such as d (0.1), d (0.5), and d (0.9). Are particles characterized by being about 21, 71, and 248 microns, respectively, or particles that have undergone minimal grinding. The relatively large particles used for spray granulation may be particles with a central particle size greater than 13 microns or oxcarbazepine particles that do not pass through a 40 micron sieve. Optionally, the spray granulated oxcarbazepine pharmaceutical composition may comprise smaller particle size oxcarbazepine particles that are spray granulated. Optionally, the oxcarbazepine dispersion used for spray granulation has a multimodal oxcarbazepine particle size distribution similar to oxcarbazepine in a multimodal oxcarbazepine pharmaceutical composition. Also good.

  According to another embodiment, the sprayed oxcarbazepine dispersion comprises relatively small oxcarbazepine particles. These relatively small particles comprise, for example, oxcarbazepine particles obtained after the grinding process. Alternatively, such a dispersion of relatively small oxcarbazepine particles provides a dispersion comprising relatively large oxcarbazepine particles, and the particle size of the oxcarbazepine particles in the dispersion is preferably It is obtained by reducing by a high pressure crushing process. The relatively small particles used for spray granulation may be particles with a central particle size of less than 6 microns, preferably less than 3 microns. Optionally, the spray granulated oxcarbazepine pharmaceutical composition may comprise larger particle size oxcarbazepine particles that are spray granulated. Optionally, the oxcarbazepine dispersion used for spray granulation has a multimodal oxcarbazepine particle size distribution similar to oxcarbazepine in a multimodal oxcarbazepine pharmaceutical composition. Also good.

  Spray granulated oxcarbazepine pharmaceutical compositions include tablet and capsule fillers and diluents (eg, microcrystalline cellulose, lactose, starch, and tribasic calcium phosphate), disintegrants (eg, starch, croscarmellose sodium, and Sodium starch glycolate), binders (such as starch, hydroxypropylmethylcellulose, and povidone), glidants (such as colloidal silicon dioxide), lubricants (such as magnesium stearate, magnesium lauryl sulfate, and sodium stearyl fumarate) And at least one excipient selected from the group of surfactants and wetting agents (eg, sodium lauryl sulfate, polysorbate, and poloxamer). According to a preferred embodiment, the spray dispersion of oxcarbazepine comprises a binder such as hypromellose.

  The present invention also discloses a method for producing a pharmaceutical composition of spray granulated oxcarbazepine. The method includes spraying at least one excipient with a dispersion of oxcarbazepine. First, a dispersion of oxcarbazepine is prepared, and the dispersion of oxcarbazepine is sprayed onto the fluid excipient particles and then dried. Drying is preferably performed rapidly in a flowing / floating gas (usually air). This spraying method is preferably performed by an apparatus using a fluidized bed technique in which particles are suspended in a vertical column by a rising air stream. While the particles are flowing, the coated dispersion of oxcarbazepine is sprayed into the column. This spraying can be done by any of three methods: top spray, bottom spray, and “tangential” or powder spray. Among them, it is preferable to spray the oxcarbazepine dispersion by the upward spraying method.

  Furthermore, the preferred spray granulation method of the present invention is slightly different from commonly used spray granulation methods. In a commonly used procedure, the granulation solution is sprayed onto a mixture of active and inactive substances that float or flow in air. According to the preferred spray granulation method of the invention, a dispersion of the active substance is sprayed onto an excipient that is suspended in the air or onto a mixture of active and inactive substances.

  In particular, in the above-described spray granulation method, if two granulated products, one containing small oxcarbazepine particles and the other containing large oxcarbazepine particles, are prepared separately, the present invention. Further advantages are exhibited. In many cases, it is important to adjust and fine tune the dissolution characteristics of the final pharmaceutical composition during development. If the elution rate is determined for each granulated product, such elution rate can be finely adjusted very easily for the final pharmaceutical composition. By simply mixing two or more kinds of granular materials at an appropriate ratio, the resulting elution rate can be set to a desired value. In order to increase the elution rate, the proportion of the particulate matter having a higher dissolution rate in the mixture of the particulate matter may be set to a high proportion accordingly. The reverse is equally simple.

  According to the pharmaceutical composition of the present invention, the dissolution rate of oxcarbazepine is comparable to that of the pharmaceutical composition comprising ground oxcarbazepine particles. This is in contrast to the expected dissolution rate for oxcarbazepine particles having a broad particle size distribution. This is because the pharmaceutical composition of the present invention comprises large / unground oxcarbazepine particles. Furthermore, according to the dissolution rate of oxcarbazepine from the pharmaceutical composition of the present invention, oxycarbazepine can be sufficiently absorbed in the gastrointestinal tract in a pH range from weakly acidic to neutral. Oxcarbazepine elutes from the pharmaceutical composition of the present invention at a suitable rate. It is preferable that 30% or more of the oxcarbazepine in the pharmaceutical composition is eluted from the pharmaceutical composition within 60 minutes in an environment simulating the gastrointestinal tract. Among them, it is more preferable that 30% or more, preferably about 40% or more, of the oxcarbazepine in the pharmaceutical composition elutes from the composition within 50 minutes in such an environment. % Or more is most preferably eluted from the pharmaceutical composition within 35 minutes under such circumstances. The preferable dissolution rate of oxcarbazepine from the pharmaceutical composition of the present invention in an environment simulating the gastrointestinal tract can also be expressed as follows. That is, a) about 30% or less of the total amount of oxcarbazepine elutes from the composition after 35 minutes of measurement with the elution device, and b) about 30% of the total amount of oxcarbazepine after 50 minutes of measurement with the elution device. Preferably about 40% or more, up to about 50% elute from the composition, and c) about 30% to about 50% of the total amount of oxcarbazepine elutes from the composition after 60 minutes of measurement with an elution device To do. The gastrointestinal environment can be simulated by using a physiological surfactant in a medium containing an acid such as HCl, and gradually increasing the amount added to change the pH. The conditions imitating the gastrointestinal tract will be described later in Example 14, for example.

  The pharmaceutical composition of the present invention provides a bioequivalent formulation of TRILEPTAL®. The pharmaceutical composition of this embodiment of the invention (the biological equivalent of TRILEPTAL®) comprises oxcarbazepine, a hydrophilic polymer, and at least one pharmaceutical excipient, The ratio of hydrophilic polymer to carbazepine ranges from about 1: 3 to about 1:25, preferably from about 1: 5 to about 1:22, more preferably from about 1: 9 to about 1:20. It is. Furthermore, the rate of oxcarbazepine decay from the pharmaceutical composition of the present invention is sufficiently reduced so that the impact on bioavailability is minimized. The pharmaceutical composition comprising the oxcarbazepine of the present invention is prepared by the method described in USP Pharmacopeia (USP Pharmacopeia (2007); USP 30, NF 25, vol 1; <701> Disintegration, pp 276-277). The measured decay time is a suitable value. The disintegration time is preferably less than about 30 minutes, more preferably less than about 20 minutes, and most preferably less than about 15 minutes.

  Oxcarbazepine is used to treat epilepsy in patients suffering from epileptic seizures. The pharmaceutical compositions of the present invention provide an effective delivery system for administering oxcarbazepine to patients in need of such treatment. The method for treating a patient suffering from epilepsy may include a step of administering an effective amount of oxcarbazepine in the pharmaceutical composition of the present invention. This pharmaceutical composition preferably comprises oxcarbazepine with a broad particle size distribution. Furthermore, this broad oxcarbazepine particle size distribution is preferably a multimodal oxcarbazepine particle size distribution. Furthermore, oxcarbazepine has been shown to be effective in treating Parkinson's disease. Thus, the pharmaceutical composition of the present invention also provides an effective delivery system for administering oxcarbazepine to patients suffering from Parkinson's disease and neuropathic pain.

  The following examples are provided to further illustrate the present invention. These examples should not be construed as limiting the invention in any way.

  A formulation comprising an oxcarbazepine having a broad particle size distribution and at least one pharmaceutical excipient was prepared. Some of the following examples demonstrate the persistence of multimodal tablet formulations. In order to evaluate the d (0.5) oxcarbazepine particle size distribution of the multimodal formulation, two strategies were chosen and implemented. 1) Preparation of multimodal oxcarbazepine mixtures and analysis of their particle size distribution using laser diffractometry (Malvern Mastersizer S), and 2) PSD of large and small oxcarbazepines This is a measure of calculating d (0.1), d (0.5), and d (0.9) numerically by weighted average calculation. As an example, the following table shows the results of numerical calculations of PSD for a multimodal mixture containing small and large oxcarbazepine particles, respectively, in a ratio of 35:65.

Calculation procedure:
1. Data:% cumulative volume of small and large oxcarbazepine.
2. Each integrated volume% is multiplied by a percentage (35% or 65% in this embodiment).
3. Sum of 35% product and 65% product.

Example 1: Preparation of a multimodal oxcarbazepine formulation in a 10:90 ratio

  In the first step 1, a starting dispersion was prepared from large oxcarbazepine. 1200 g of large oxcarbazepine raw material (RM) [d (0.9) = 248.5] was dispersed in a solution containing 240 g of hypromellose (Pharmacoat 603) in 4800 g of purified water. Pharmacoat was added to water and stirred until a clear mixture was obtained. Subsequently, the large oxcarbazepine was added to the mixture of Pharmacoat and water and dispersed using a rotor stirrer (Brogtec) over about 30 minutes. This large oxcarbazepine particle size distribution was measured by laser diffraction method (Malvern Mastersizer S), and was as follows.

  In the second step 2, a high pressure homogenization process (MFIC microfluidizer M-110F) was performed to reduce the particle size of the large oxcarbazepine. This particle size reduction by wet milling was carried out in the presence of a hydrophilic polymer or hypromellose (hydroxypropylmethylcellulose, eg Pharmacoat®) as a stabilizer. The particle size distribution of the final oxcarbazepine dispersion (small oxcarbazepine) was measured by a laser diffraction method (Malvern Mastersizer S), and was as follows.

  In the third step 3, the fluid bed upward spray granulation process was performed with the final dispersion of small oxcarbazepine as the spray granulation dispersion. The components contained in this granulated preparation are as follows.

  In the fourth step 4, large oxcarbazepine granules were prepared with a high shear mixer. The formulation of the large oxcarbazepine granule was as follows.

  When the particle size distribution of the large oxcarbazepine RM used for granulation was measured by a laser diffraction method (Malvern mastersizer S), it was as follows.

  In the final fifth step 5, a granulation mixture and a tablet were prepared. The spray granulated product of Step 3 was mixed with the granulated product of Step 4 in a ratio of 9: 1 each. A mixture of these two granulates was prepared to prepare a 600 mg dose. Here, the spray granulated product contained 540 mg of the active substance, and the granulated product of Step 4 contained 60 mg of the active substance. The resulting final formulation containing the lubricant as a further excipient is as follows:

  Subsequently, the granulated mixture was pressure-molded into tablets, and elution was performed. The observed dissolution rate was comparable to the TRILEPTAL® bioequivalent formulation as shown in FIG.

  The particle size of the oxcarbazepine used in this example is estimated to have d (0.5) on the order of 0.6 microns and about 6% of the material is retained on a 40 micron sieve. It was. A method for measuring such an approximate value is illustrated below. In order to evaluate the d (0.5) of the 10/90 ratio multimodal oxcarbazepine formulation, mixing of the two dispersions was performed. The mixture comprises 90% small particles characterized by d (0.5) of 0.7 microns and 10% large particles characterized by d (0.5) of 68 microns. Contained. The d (0.5) of this mixture was measured by malvern and found to be 0.7 microns. To evaluate the amount of oxcarbazepine retained on a 40 micron screen, a large oxcarbazepine sieve analysis was performed with alpine. The results of sieve analysis indicated that about 60% of the oxcarbazepine was retained on a 40 micron sieve. Thus, assuming that none of the “small” oxcarbazepine particles obtained after sieving are retained on a 40 micron mesh screen, more than 6% of the 90/10 mixture is on the 40 micron sieve. It is thought to be retained.

Example 2: Preparation of a multimodal oxcarbazepine formulation in a ratio of 1: 5

  The first four steps were performed as in Example 1. In the final step 5 of preparing the granulation mixture and tablets, the spray granulation was mixed with the granulation of step 4 in a ratio of 16.6: 83.3 respectively. A mixture of these two granulates was prepared to prepare a 600 mg dose. Here, the spray granulated product contained 500 mg of the active substance, and the mixed granulated product contained 100 mg of the active substance. The resulting final formulation containing the lubricant as a further excipient is as follows:

  Subsequently, the granulated mixture was pressure-molded into tablets, and elution was performed. The observed dissolution rate was comparable to the TRILEPTAL® bioequivalent formulation as shown in FIG. The particle size of the oxcarbazepine used in this example is estimated to have d (0.5) on the order of 0.7 microns and about 10% of the material is retained on a 40 micron sieve. It was. A method for measuring such an approximate value is illustrated below. In order to evaluate the d (0.5) of the 1: 5 multimodal oxcarbazepine formulation, mixing of the two dispersions was performed. This mixture has 80% small particles characterized by d (0.5) of 0.7 microns and 20% large particles characterized by d (0.5) of 68 microns. Contained. The d (0.5) of this mixture was measured by malvern and found to be 0.8 microns. Therefore, d (0.5) when the ratio is 1: 5 is also less than 0.8 microns. To evaluate the amount of oxcarbazepine retained on a 40 micron screen, a large oxcarbazepine sieve analysis was performed with alpine. The results of sieving analysis showed that about 60% of the oxcarbazepine was retained on the sieving. Thus, assuming that none of the small oxcarbazepine particles obtained after sieving are retained on a 40 micron mesh screen, a 1: 5 mixture retains about 10% or more on a 40 micron sieve. It is thought that it is done.

Example 3: Preparation of a 55:45 multimodal oxcarbazepine formulation using a combination of spray granulation and mixed granulation

  The first three steps were performed as in Example 1. In Step 4, an oxcarbazepine granule [d (0.5) = 30.5] was prepared by a wet granulation process. The formulation of the large oxcarbazepine granulation was as follows.

  The particle size distribution of the large oxcarbazepine RM for granulation was measured by a laser diffraction method (Malvern mastersizer S).

  In the final fifth step 5, a granulation mixture and a tablet were prepared. The granulated product of Step 3 was mixed with the mixed granulated product of Step 4 in a ratio of 45:55, respectively. A mixture of these two granulates was prepared to prepare a 600 mg dose. Here, the spray granulated product contained 270 mg of the active substance, and the mixed granulated product of Step 4 contained 330 mg of the active substance. The resulting final formulation containing the lubricant as a further excipient is as follows:

  Subsequently, the granulation mixture was pressure-molded into tablets, and a dissolution test was performed. The observed dissolution rate was comparable to the TRILEPTAL® bioequivalent formulation, as shown in FIG.

Example 4: Preparation of a 65:35 ratio multimodal oxcarbazepine formulation using spray granulation in combination with mixed granulation

  The first four steps were performed as in Example 3. In the final step 5 of preparing the granulation mixture and tablets, the spray granulation was mixed with the mixed granulation in a ratio of 35:65, respectively. A mixture of these two granulates was prepared to prepare a 600 mg dose. Here, the spray granulated product (small) contained 210 mg of the active substance, and the mixed granulated product (large) of Step 4 contained 390 mg of the active substance. The resulting final formulation containing the lubricant as a further excipient is as follows:

  Subsequently, the granulation mixture was pressure-molded into tablets, and a dissolution test was performed. The observed dissolution rate was comparable to that of the TRILEPTAL® bioequivalent formulation, as shown in FIG.

  A numerical calculation was performed to evaluate d (0.5) of the 65:35 mixture. The oxcarbazepine d (0.5) contained 65% of the population of d (0.5) = 27.6 microns and 35% of the population of d (0.5) = 0.8. Calculation results show that the d (0.5) of this mixture is about 13 microns.

Example 5: Preparation of a 65:35 multimodal oxcarbazepine formulation using a combination of two spray granulates

  The first three steps were performed as in Example 1. In step 4, a dispersion for spray granulation is prepared. 60 g of large oxcarbazepine raw material (RM) [d (0.9) = 248.5] was dispersed in a solution containing 12 g of hypromellose (Pharmacoat 603) in 240 g of purified water. Pharmacoat was added to water to make a clear mixture. Subsequently, the large oxcarbazepine was added to the Pharmacoat water mixture and dispersed for about 30 minutes using a rotor stirrer (Brogtec) to form a large oxcarbazepine dispersion. The particle size distribution of the large oxcarbazepine obtained after the process by the rotor stirrer was measured by a laser diffraction method (Malvern Mastersizer S).

  In step 5, the large oxcarbazepine dispersion was used as the spray granulation dispersion in the fluid bed upward spray granulation process. The granulated formulation contained the following ingredients:

  In the final sixth step 6, a granulation mixture and tablets were prepared. The spray granulated product of Step 3 was mixed with the spray granulated product of Step 5 in a ratio of 35:65, respectively. A mixture of these two granulates was prepared to prepare a 600 mg dose. Here, the spray granulated product contained 210 mg of the active substance, and the spray granulated product of Step 5 contained 390 mg of the active substance. The resulting final formulation containing the lubricant as a further excipient is as follows:

  Subsequently, the granulation mixture was pressure-molded into tablets, and a dissolution test was performed. The observed dissolution rate was comparable to the TRILEPTAL® bioequivalent formulation as shown in FIG.

  A numerical calculation was performed to evaluate d (0.5) of this 65:35 mixture. Calculation results showed that the resulting d (0.5) of this mixture was about 13 microns.

Example 6: Preparation of a 55:45 multimodal oxcarbazepine formulation using a combination of two spray granulates

  The first five steps were performed as in Example 5. In the final step 6 of preparing the granulation mixture and tablet, the spray granulation from step 3 was mixed with the spray granulation from step 5 in a ratio of 45:55, respectively. A mixture of these two granulates was prepared to prepare a 600 mg dose. Here, the spray granulated product of Step 3 contained 270 mg of the active substance, and the spray granulated product of Step 5 contained 330 mg of the active substance. The resulting final formulation containing the lubricant as a further excipient is as follows:

  Subsequently, the granulation mixture was pressure-molded into tablets, and a dissolution test was performed. The observed dissolution rate was comparable to the TRILEPTAL® bioequivalent formulation as shown in FIG.

Example 7: Preparation of a relatively slowly dissolving pharmaceutical composition

  A biological non-equivalent formulation consisting of a relatively slow-eluting pharmaceutical composition was prepared using oxcarbazepine characterized by d (0.5) of 43 microns. Oxcarbazepine granulation was prepared using a high shear mixer and dried in a fluid bed dryer. The final formulation containing the lubricant as a further excipient was as follows:

  The final blend was compression molded into tablets and the tablets were coated.

Example 8: Preparation of spray granulated oxcarbazepine formulation

  In the first step, a starting dispersion was prepared from large oxcarbazepine. 60 g of a large oxcarbazepine raw material (RM) [d (0.9) = 248.5] was dispersed in a solution containing 12 g of hypromellose (Pharmacoat 603) in 240 g of purified water. Pharmacoat was added to the water and mixed until a clear mixture was obtained. Subsequently, large oxcarbazepine was added to the Pharmacoat water mixture and dispersed using a rotor stirrer (Brogtec) for 30 minutes at 9000 rpm. When the particle size distribution of the oxcarbazepine after the process by the rotor stirrer was measured by a laser diffraction method (Malvern Mastersizer S), it was as follows.

  In the second step, the large oxcarbazepine dispersion was used as the spray granulation dispersion in the fluid bed upward spray granulation process. The granulate formulation contained the following substances:

  Subsequently, in the third step, the granulation mixture was pressure-molded into tablets, and a dissolution test was performed. The observed dissolution rate was about the same as that of the TRILEPTAL (registered trademark) bioequivalent preparation, as shown in FIG.

  As the particle size of the oxcarbazepine used in this example, d (0.5) is on the order of 27 microns, and it is estimated that about 29% or more of this material is retained on a 40-micron sieve. It was. The procedure for making such an estimation is illustrated below. To evaluate the amount of oxcarbazepine retained on a 40 micron screen, large oxcarbazepine sieve analysis was performed using a “Fritsch” vibratory sieve shaker for wet sieving. . In this test, a large oxcarbazepine characterized by d (0.5) of 16 microns was used. Sieve analysis results showed that about 29% of the oxcarbazepine was retained on a 40 micron screen. Therefore, it is clear that if the sieving test of the large oxcarbazepine used in Examples 8 and 9 is performed, the result that 29% or more is retained on the 40 micron sieve is obtained.

Example 9: Preparation of spray granulated oxcarbazepine formulation using extra-granular excipient

  The first two steps were performed as in Example 8. In Step 3, the oxycarbazepine spray granulate was mixed with extraparticulate excipients as follows.

  Subsequently, in the fourth step, the granulation mixture was pressure-molded into tablets, and a dissolution test was performed. The observed dissolution rate was comparable to the TRILEPTAL® bioequivalent formulation, as shown in FIG.

Example 10: Preparation of spray granulated oxcarbazepine formulation

  In the first step 1, a starting dispersion was prepared from large oxcarbazepine. 30 g of large oxcarbazepine raw material (RM) [d (0.9) = 248.5] was dispersed in a solution containing 6 g of hypromellose (Pharmacoat 603) in 120 g of purified water. Pharmacoat was added to the water and mixed until a clear mixture was obtained. Subsequently, large oxcarbazepine was added to the Pharmacoat water mixture and dispersed using a rotor stirrer (Brogtec) for 30 minutes at 9000 rpm. When the particle size distribution of the large oxcarbazepine after the process by the rotor stirrer was measured by a laser diffraction method (Malvern Mastersizer S), it was as follows.

  In the second step, the large oxcarbazepine dispersion was used as the spray granulation dispersion in the fluid bed upward spray granulation process. The granulated formulation contained the following substances:

  Subsequently, in the third step, the granulation mixture was pressure-molded into tablets, and a dissolution test was performed. The observed dissolution rate was comparable to the TRILEPTAL® bioequivalent formulation, as shown in FIG.

Example 11: Preparation of spray granulated oxcarbazepine formulation using extraparticulate excipient

  The first two steps were performed as in Example 10. In Step 3, the oxcarbazepine spray granulation was mixed with extraparticulate excipients as follows.

  Subsequently, in the fourth step, the granulation mixture was pressure-molded into tablets, and a dissolution test was performed. The observed dissolution rate was comparable to the TRILEPTAL® bioequivalent formulation, as shown in FIG.

  For the formulations prepared for Examples 8, 9, 10 and 11, the spray granulation process was performed using a single oxcarbazepine population, but the particle size of the oxcarbazepine used was d (0. 5) The value is preferably between about 13 microns and about 30 microns.

  The following two examples show spray granulation formulations with oxcarbazepine such that d (0.5) is less than 2% and more than 5% is retained on a 40 micron sieve. This is just an example.

Example 12: Preparation of a 20:80 ratio multimodal oxcarbazepine formulation in which a small particle dispersion of oxcarbazepine is sprayed onto large oxcarbazepine particles in a spray granulation process.

  In the first step, a starting dispersion was prepared from large oxcarbazepine. 1500 g large oxcarbazepine raw material was dispersed in a solution containing 300 g hypromellose (Pharmacoat 603) in 6000 g purified water. Pharmacoat was added to the water and mixed until a clear mixture was obtained. Subsequently, large oxcarbazepine was added to the Pharmacoat water mixture and dispersed using a rotor stirrer (Brogtec) for about 30 minutes. The particle size distribution of the large oxcarbazepine was measured by a laser diffraction method (Malvern Mastersizer S).

  In the second step, it was subjected to a homogenization process under high pressure (MFIC microfluidizer M-110F) to reduce the particle size of the large oxcarbazepine. The particle size distribution of this final oxcarbazepine (small) dispersion (small oxcarbazepine) was measured by laser diffraction method (Malvern Mastersizer S), and was as follows.

  In the third step 3, the final dispersion of small oxcarbazepine was used as the spray granulation dispersion in the fluid bed upward spray granulation process and sprayed onto the mixture of excipients and large oxcarbazepine. The particle size distribution of the large oxcarbazepine was measured by laser diffractometry (Malvern Mastersizer S) and was as described in the first stage of the current example.

  This granulated formulation contained the following substances:

  In the fourth step, the granulation was mixed with extraparticulate excipients as shown below.

  Subsequently, the granulation mixture was pressure-molded into tablets, and a dissolution test was performed. In addition, tablets were coated.

  The observed dissolution rate was comparable to the TRILEPTAL® bioequivalent formulation, as shown in FIG. The particle size of the oxcarbazepine used in this example is estimated to have d (0.5) on the order of 0.8 microns and about 12% of this material is retained on a 40 micron sieve. The The evaluation of d (0.5) particle size and sieve analysis are shown in Example 2.

Example 13:

  The first three steps were performed as in Example 12. In Step 4, the oxycarbazepine spray granulate was mixed with extraparticulate excipients as shown below.

  Subsequently, the granulated mixture was pressure-molded into tablets, and elution was performed. Further tablets were coated.

  The observed dissolution rate was comparable to the TRILEPTAL® bioequivalent formulation, as shown in FIG. Since the granulated product was the same as that obtained in Example 12, the particle size of the oxcarbazepine used in this example was also in the order of d (0.5) of 0.8 microns. It is estimated that about 12% of the material is retained on a 40 micron sieve.

Example 14: Dissolution test The tablets described in Examples 1 to 13 were tested using a medium containing a physiological surfactant. In this procedure, in order to simulate gastrointestinal conditions, the amount added was gradually increased to change the pH. This elution procedure was performed in the USP apparatus II by the paddle method at 37 ° C. and 50 rpm under the conditions shown in Table 2 below.

  The concentration of eluted oxcarbazepine was measured at 35, 50, and 60 minutes. Since the lecithin solution is turbid, it is preferable to clean the specimen before measurement by UV. In order to compare the elution profile with a commercially available pharmaceutical composition, a pharmaceutical composition bioequivalent to TRILEPTAL® was also subjected to the elution experiment. Table 4 lists the tablets of Examples 1-6 and 8-13, the TRILEPTAL® bioequivalent tablet (“Trileptal® bioequivalent composition A”), as well as prepared in accordance with the present invention. Moreover, the elution profile is shown for each relatively slow-eluting pharmaceutical composition (Example 7).

  The results of six experiments conducted individually are shown. FIG. 1 shows the results of dissolution tests under the conditions described above for TRILEPTAL® bioequivalent composition A and Examples 1 and 2. Similarly, FIG. 2 shows the results of dissolution tests for TRILEPTAL® bioequivalent composition A, a relatively slow composition (Example 7), and Examples 3 and 4. FIG. 3 shows the results of dissolution tests under the same dissolution conditions for TRILEPTAL (registered trademark) Bioequivalent Composition A, Slowly Dissolving Composition (Example 7), and Examples 5 and 6. . FIG. 4 shows the results of dissolution tests under the same dissolution conditions for TRILEPTAL (registered trademark) Bioequivalent Composition A, Slowly Dissolving Composition (Example 7), and Examples 8 and 9. . FIG. 5 shows the results of dissolution tests under the same dissolution conditions for TRILEPTAL (registered trademark) bioequivalent composition A, slowly soluble composition (Example 7), and Examples 10 and 11. . FIG. 6 shows the results of dissolution tests under the same dissolution conditions for TRILEPTAL (registered trademark) Bioequivalent Composition A, Slowly Dissolving Composition (Example 7), and Examples 12 and 13. . Finally, in FIG. 7, the results of dissolution tests under the same dissolution conditions for TRILEPTAL (registered trademark) bioequivalent composition A, slowly-dissolving composition (Example 7), and Examples 15 and 16 are shown. Show.

  In the results, the numerical values in Table 3 for TRILEPTAL® bioequivalent compositions represent the average values in 6 experiments, and the numerical values in Table 3 for the slowly soluble composition are the averages in 4 experiments. It represents a value. In Table 3, the dissolution profiles of various pharmaceutical compositions are shown as a percentage of oxcarbazepine eluted from the composition.

  The bioavailability of oral tablets appears to be affected by disintegration and dissolution. In order to reduce the disintegration time of small particles in oxcarbazepine formulations, in the spray granulation process using hypromellose, the hypromellose used in spraying small oxcarbazepine on large oxcarbazepine particles Reduced the amount. The following two examples (15 and 16) demonstrate the formulations obtained in this way with a reduced amount of hypromellose and less than the amount of hypromellose in Examples 1-13 above.

Example 15: Preparation of a 20:80 multimodal oxcarbazepine formulation using 43.2 mg of hypromellose

  In the first step 1, a starting dispersion was prepared from large oxcarbazepine. 1800 g of large oxcarbazepine raw material was dispersed in a solution containing 162 g of hypromellose (HPMC, Pharmacoat 603) in 3860 g of purified water. Pharmacoat was added to water and stirred until a clear mixture was obtained. Subsequently, large oxcarbazepine was added to the mixture of Pharmacoat and water and mixed well. This large oxcarbazepine particle size distribution was measured by laser diffraction method (Malvern Mastersizer S), and was as follows.

  In the second step 2, a high pressure homogenization process (MFIC microfluidizer M-110F) was performed to reduce the particle size of the large oxcarbazepine. The particle size distribution of this final oxcarbazepine (small) dispersion (small oxcarbazepine) was measured by laser diffraction method (Malvern Mastersizer S), and was as follows.

  In the third step 3, this final dispersion of small oxcarbazepine is used as the spray granulation dispersion in the fluid bed upward spray granulation process and sprayed onto the mixture of excipients and large oxcarbazepine. did. The particle size distribution of the large oxcarbazepine was measured by a laser diffraction method (Malvern Mastersizer S), and was as described in the first stage of the current example.

  This granulated formulation contained the following substances:

  In the fourth step, the granulation was mixed with extraparticulate excipients as shown below.

  Subsequently, the granulation mixture was pressure-molded into tablets, and a dissolution test was performed. In addition, tablets were coated.

  The observed dissolution rate was comparable to the TRILEPTAL® bioequivalent formulation as shown in FIG. When d (0.5) of the oxcarbazepine used in this example was measured by a laser diffraction method (Malvern Mastersizer S), it was 0.90 micron. The amount retained on the 40 micron sieve was 13%.

Example 16: Preparation of a 20:80 multimodal oxcarbazepine formulation using 30 mg hypromellose

  In the first step 1, a starting dispersion was prepared from large oxcarbazepine. 1800 g of large oxcarbazepine raw material was dispersed in a solution containing 113 g of hypromellose (Pharmacoat 603) in 3800 g of purified water. Pharmacoat was added to water and stirred until a clear mixture was obtained. Subsequently, large oxcarbazepine was added to the mixture of Pharmacoat and water and mixed well. This large oxcarbazepine particle size distribution was measured by laser diffraction method (Malvern Mastersizer S), and was as follows.

  In the second step 2, a high pressure homogenization process (MFIC microfluidizer M-110F) was performed to reduce the particle size of the large oxcarbazepine. The particle size distribution of this final oxcarbazepine (small) dispersion (small oxcarbazepine) was measured by laser diffraction method (Malvern Mastersizer S), and was as follows.

  In the third step 3, this final dispersion of small oxcarbazepine is used as the spray granulation dispersion in the fluid bed upward spray granulation process and sprayed onto the mixture of excipients and large oxcarbazepine. did. The particle size distribution of the large oxcarbazepine was measured by a laser diffraction method (Malvern Mastersizer S), and was as described in the first stage of the current example.

  This granulated formulation contained the following substances:

  In the fourth step, the granulation was mixed with extraparticulate excipients as shown below.

  Subsequently, the granulation mixture was pressure-molded into tablets, and a dissolution test was performed. In addition, tablets were coated.

  The observed dissolution rate was comparable to the TRILEPTAL® bioequivalent formulation as shown in FIG. When d (0.5) of the oxcarbazepine used in this example was measured by a laser diffraction method (Malvern Mastersizer S), it was 0.90 micron. The amount retained on the 40 micron sieve was 13%.

Example 17: Examination of single dose, relative bioavailability of a composition according to the invention in comparison with TRILEPTAL® 600 mg commercial composition

We tested the relative bioavailability of healthy subjects. The following compositions were tested:
1. 1. Composition according to the invention: coated tablet prepared according to Example 15 Commercially available TRILEPTAL (registered trademark) 600 mg tablet

  The test was performed by administering a single dose of 600 mg oxcarbazepine to 15 healthy individuals. There was a minimum 6-day drug holiday between doses. Samples for pharmacokinetic analysis were taken at predetermined time intervals. The oxcarbazepine content in plasma was measured for each sample.

  The resulting geometric mean and the ratio between them are shown in the table below.

  From the above results, it can be seen that the ratio of Cmax and AUC0-inf of the tested composition to the control product is between 80% and 125%. Thus, it is clear that the compositions described in the present invention show relative bioavailability data similar to the control TRILEPTAL®.

Example 18
The disintegration time of the formulation in water was tested using a disintegrator (Disintegrator Erweka ZT41).

  The results are shown in the table below.

Example 19-Examination of single dose, relative bioavailability of a composition according to the invention in comparison with TRILEPTAL® 600 mg bioequivalent composition

We tested the relative bioavailability of healthy subjects. The following compositions were tested:
1. TRILEPTAL® bioequivalent composition A.
2. Commercially available TRILEPTAL (registered trademark) 600 mg tablet.

  The test was conducted by administering a single dose of 600 mg oxcarbazepine to 57 healthy individuals. There was a minimum 6-day drug holiday between doses. Samples for pharmacokinetic analysis were taken at predetermined time intervals. The oxcarbazepine content in plasma was measured for each sample.

  The ratio of Cmax and AUC between the test formulation and the control formulation is shown in the table below.

  From the above results it can be seen that the ratio of Cmax and AUC (0-inf) of the tested composition to the control product is between 80% and 125%. Thus, it is clear that the compositions described in the present invention show relative bioavailability data similar to the control TRILEPTAL®.

Example 20:
Wet sieving method for determining the amount of oxcarbazepine retained on a 40μ sieve

1. Purpose Measurement of the amount of oxcarbazepine retained on a 40μ sieve.

2. apparatus
* Sieving device: Fritsch; Vibrating sieve shaker “analysette 3”
* Sieve: 40μm

3. Method parameter sieving time: 3 minutes Amplitude: Double interval: 5 seconds

4). Method summary:
Oxcarbazepine was weighed and poured onto a sieve. The sieve shaker was operated under the parameters described above and the water began to flow. After completion of the sieving process, the sieve (containing the remaining oxcarbazepine) was dried in an oven and the amount of oxcarbazepine retained on the 40 μm sieve was weighed.

The dissolution profile of oxcarbazepine tablets (prepared according to Examples 1 and 2) under conditions simulating the gastrointestinal tract is shown in contrast to the TRILEPTAL® bioequivalent formulation. The dissolution profiles of oxcarbazepine tablets (prepared according to examples 3 and 4) under conditions simulating the gastrointestinal tract were prepared with the TRILEPTAL® bioequivalent formulation (prepared according to example 7). Shown in comparison with biologically non-equivalent formulations. The dissolution profiles of oxcarbazepine tablets (prepared according to Examples 5 and 6) under conditions simulating the gastrointestinal tract were prepared using the TRILEPTAL® bioequivalent formulation (prepared according to Example 7). Shown in comparison with biologically non-equivalent formulations. The dissolution profiles of oxcarbazepine tablets (prepared according to Examples 8 and 9) under conditions simulating the gastrointestinal tract are shown relative to the TRILEPTAL® bioequivalent formulation. The dissolution profiles of oxcarbazepine tablets (prepared according to Examples 10 and 11) under conditions simulating the gastrointestinal tract were prepared using the TRILEPTAL® bioequivalent formulation and (prepared according to Example 7). Shown in comparison with biologically non-equivalent formulations. The dissolution profiles of oxcarbazepine tablets (prepared according to examples 12 and 13) under conditions simulating the gastrointestinal tract were prepared with the TRILEPTAL® bioequivalent formulation (prepared according to example 7). Shown in comparison with biologically non-equivalent formulations. The dissolution profiles of oxcarbazepine tablets (prepared according to Examples 15 and 16) are shown in contrast to TRILEPTAL® bioequivalent and bionon-equivalent formulations.

Claims (98)

  A pharmaceutical composition comprising a) oxcarbazepine and b) at least one pharmaceutical excipient, wherein the oxcarbazepine in the composition has a broad particle size distribution Composition.   In the broad particle size distribution, a difference between a d (0.5) value and a d (0.95) value is larger than 38 microns, and the d (0.5) value is 35 microns or less. The pharmaceutical composition as described.   The broad particle size distribution has a value of d (0.5) selected from the range of 12 to 35 and the range of 0.01 μ to 2.0 μ, and 40 μm The pharmaceutical composition according to claim 1, wherein the minimum residue on the sieve is greater than 5%.   The pharmaceutical composition of claim 1, wherein the median particle size of the oxcarbazepine is 2 microns or less and the minimum residue on a 40 micron sieve is greater than 5%.   The pharmaceutical composition of claim 1, wherein the oxcarbazepine population has a d (0.5) of 13 microns or more and a minimum residue on a 40 micron sieve of greater than 5%.   The pharmaceutical composition according to claim 1, wherein d (0.5) of the oxcarbazepine population is 2 to 12 microns and the minimum residue on a 40 micron sieve is greater than 5%.   The pharmaceutical composition according to any one of the preceding claims, wherein the broad particle size distribution comprises a multi-modal oxcarbazepine particle size distribution.   8. The pharmaceutical composition according to claim 7, wherein the multimodal oxcarbazepine particle size distribution comprises one unground oxcarbazepine particle population.   8. The pharmaceutical composition of claim 7, wherein the multimodal oxcarbazepine particle size distribution comprises at least one particle population having a d (0.5) of about 13 microns or greater.   10. The pharmaceutical composition of claim 9, wherein d (0.5) of the at least one particle population is about 40 microns or greater.   11. The pharmaceutical composition according to claim 10, wherein d (0.5) of the at least one particle population is about 60 microns or more.   The multimodal oxcarbazepine particle size distribution is composed of an oxcarbazepine particle population having a d (0.5) value of 13 microns or more, an unmilled particle population, particles that do not pass through a 40-micron sieve, and a mixture thereof. At least one large oxcarbazepine particle population selected from the group, and about 6% by weight of the large oxcarbazepine particle population relative to the total amount of oxcarbazepine in the pharmaceutical composition The pharmaceutical composition according to any one of claims 7 to 11, comprising the above.   13. The pharmaceutical composition according to claim 12, comprising a large oxcarbazepine particle population of about 10% by weight or more based on the total amount of oxcarbazepine in the pharmaceutical composition.   The pharmaceutical composition according to claim 13, comprising about 20% by weight or more of a large oxcarbazepine particle population based on the total amount of oxcarbazepine in the pharmaceutical composition.   15. The pharmaceutical composition according to claim 14, comprising a large oxcarbazepine particle population of about 40% by weight or more based on the total amount of oxcarbazepine in the pharmaceutical composition.   8. The pharmaceutical composition of claim 7, wherein the multimodal oxcarbazepine particle size distribution comprises at least one population of small oxcarbazepine particles having a d (0.5) of less than about 6 microns.   17. The pharmaceutical composition of claim 16, wherein d (0.5) of the small oxcarbazepine particle population is less than about 3 microns.   18. The pharmaceutical composition of claim 17, wherein d (0.5) of the small oxcarbazepine particle population is less than about 2 microns.   The pharmaceutical composition according to any one of claims 16 to 18, comprising about 5% or more of small oxcarbazepine particles relative to the total amount of oxcarbazepine in the pharmaceutical composition.   The pharmaceutical composition according to claim 19, comprising about 10% or more of small oxcarbazepine particles relative to the total amount of oxcarbazepine in the pharmaceutical composition.   21. The pharmaceutical composition according to claim 20, comprising about 20% or more of small oxcarbazepine particles relative to the total amount of oxcarbazepine in the pharmaceutical composition.   The pharmaceutical composition according to claim 21, comprising about 80% or more of small oxcarbazepine particles relative to the total amount of oxcarbazepine in the pharmaceutical composition.   at least one large oxy selected from the group consisting of an oxcarbazepine particle population having a d (0.5) value of 13 microns or greater, an unmilled particle population, particles that do not pass through a 40 micron sieve, and mixtures thereof A carbazepine particle population, and from about 51 wt% to about 95 wt% large oxcarbazepine particles, and about 5 wt% based on the total weight of oxcarbazepine in the pharmaceutical composition; 19. A pharmaceutical composition according to any one of claims 16 to 18 comprising from about 49% by weight of small oxcarbazepine particles.   The small oxcarbazepine particle population ranges from about 10% to about 45% by weight, and the large oxcarbazepine particle population is about 55% by total weight of the oxcarbazepine in the pharmaceutical composition. 24. The pharmaceutical composition of claim 23, wherein the composition ranges from wt% to about 90 wt%.   at least one large oxy selected from the group consisting of an oxcarbazepine particle population having a d (0.5) value of 13 microns or greater, an unmilled particle population, particles that do not pass through a 40 micron sieve, and mixtures thereof And further comprising about 6% to about 40% by weight of large oxcarbazepine particles and about 60% by weight based on the total weight of oxcarbazepine in the pharmaceutical composition. 19. A pharmaceutical composition according to any one of claims 16 to 18 comprising from about 94% by weight of small oxcarbazepine particles.   The small oxcarbazepine particle population ranges from about 65% to about 90% by weight with respect to the total weight of oxcarbazepine in the pharmaceutical composition, and the large oxcarbazepine particle population is about 10%. 26. The pharmaceutical composition according to claim 25, wherein the composition ranges from wt% to about 35 wt%.   6. The method of claim 1, further comprising a hydrophilic polymer and wherein the weight ratio of the hydrophilic polymer to oxcarbazepine ranges from about 1: 3 to about 1:25. Pharmaceutical composition.   28. The pharmaceutical composition according to claim 27, wherein the hydrophilic polymer is hydroxypropylmethylcellulose.   29. The pharmaceutical composition according to any one of claims 27 and 28, wherein the weight ratio of hydrophilic polymer to oxcarbazepine ranges from about 1: 5 to about 1:22.   30. The pharmaceutical composition of claim 29, wherein the weight ratio of the hydrophilic polymer to oxcarbazepine ranges from about 1: 9 to about 1:20.   The pharmaceutical composition according to any one of claims 27 and 28, wherein the total amount of the hydrophilic polymer in the pharmaceutical composition is 120 mg or less.   32. The pharmaceutical composition of claim 31, wherein the total amount of hydrophilic polymer in the pharmaceutical composition ranges from about 20 mg to 120 mg.   34. The pharmaceutical composition of claim 32, wherein the total amount of hydrophilic polymer in the pharmaceutical composition ranges from about 20 mg to 50 mg.   34. The pharmaceutical composition of claim 33, wherein the total amount of hydrophilic polymer in the pharmaceutical composition ranges from about 30 mg to 45 mg.   29. A medicament according to any one of claims 27 and 28, wherein the amount of hydrophilic polymer in the pharmaceutical composition ranges from about 1% to about 15% by weight relative to the weight of the composition. Composition.   36. The pharmaceutical composition of claim 35, wherein the amount of hydrophilic polymer in the pharmaceutical composition ranges from about 2% to about 12% by weight relative to the weight of the composition.   37. The pharmaceutical composition of claim 36, wherein the amount of hydrophilic polymer in the pharmaceutical composition ranges from about 2% to about 4% by weight relative to the weight of the composition.   38. The pharmaceutical composition according to any one of claims 27 and 37, wherein the multimodal particle size distribution comprises at least one small particle population.   39. The pharmaceutical composition according to claim 38, wherein the small particle population is spray granulated.   40. The pharmaceutical composition according to any one of claims 27 to 39, wherein the weight ratio of the hydrophilic polymer to the small oxcarbazepine particle population ranges from about 1: 3 to about 1:20.   41. The pharmaceutical composition of claim 40, wherein the weight ratio of the hydrophilic polymer to the small oxcarbazepine particle population ranges from about 1: 5 to about 1:18.   42. The pharmaceutical composition of claim 41, wherein the weight ratio of the hydrophilic polymer to the small oxcarbazepine particle population ranges from about 1: 9 to about 1:17.   A pharmaceutical composition according to any preceding claim, wherein the composition is a biological equivalent of TRILEPTAL®. A method for preparing a pharmaceutical composition comprising oxcarbazepine having a multimodal oxcarbazepine particle size distribution comprising:
a) preparing an oxcarbazepine comprising two or more oxcarbazepine particle populations having different particle size distributions;
b) providing at least one excipient;
c) forming at least one particulate comprising at least one of the oxcarbazepine population, and
d) A method comprising the step of mixing the granulated oxcarbazepine with the remainder of the ungranulated oxcarbazepine and at least one excipient.   45. The method of claim 44, wherein at least one of the two or more oxcarbazepine particle populations having different particle size distributions is granulated separately.   46. The method of claim 45, wherein the two or more oxcarbazepine particle populations having different particle size distributions are prepared by milling a portion of the total amount of oxcarbazepine that forms the small oxcarbazepine particle population. .   47. The method of claim 46, further comprising de-agglomerating a portion of the total amount of oxcarbazepine.   48. The method of claim 47, wherein the crushing is performed by milling a portion of the total amount of the oxcarbazepine.   49. The method according to any one of claims 46 to 48, wherein milling is carried out in a dispersion using a high-pressure crusher.   The method according to any one of claims 46 to 49, wherein only the milling is performed such that the residue retains a large particle size distribution with respect to the residue of the total amount of the oxcarbazepine.   The milling is performed by a milling process selected from the group consisting of a process using a low pulverization pressure air jet mill and a process in a dispersion using a crusher having a low rotation speed. the method of. d) mixing the granulate with one or more excipients to form a tableting mixture; and
52. The method according to any one of claims 44 to 51, further comprising e) pressing the tableting mixture into a tablet.   A pharmaceutical composition comprising a) spray granulated oxcarbazepine and b) at least one pharmaceutical excipient.   54. The pharmaceutical composition of claim 53, wherein the oxcarbazepine d (0.5) is 2 microns or less and the minimum residue on a 40 micron sieve is greater than 5%.   54. The pharmaceutical composition of claim 53, wherein the oxcarbazepine d (0.5) is greater than or equal to 13 microns and the minimum residue on a 40 micron sieve is greater than 5%.   54. The pharmaceutical composition of claim 53, wherein the oxcarbazepine has a d (0.5) particle size of 2 to 12 microns and a minimum residue on a 40 micron sieve is greater than 5%.   The oxcarbazepine in the composition has at least two populations of different particle sizes, and at least one of the oxcarbazepine particle populations comprises spray granulated oxcarbazepine. Item 56. The pharmaceutical composition according to any one of Items 53 to 56.   58. The pharmaceutical composition according to claim 57, wherein the large oxcarbazepine particle population is spray granulated.   The large oxcarbazepine particle population comprises an oxycarbamate having a d (0.1) of about 21 microns, a d (0.5) of about 71 microns, and a d (0.9) of about 248 microns. Zepin particle population, oxycarbazepine population with minimal grinding, unground oxcarbazepine population, oxcarbazepine with particles having a d (0.5) value greater than 13 microns 59. The pharmaceutical composition of claim 58, selected from the group consisting of a population, a population of oxcarbazepine particles that do not pass through a 40 micron sieve, and mixtures thereof.   60. The pharmaceutical composition according to any one of claims 57 to 59, wherein the amount of the large oxcarbazepine particle population is about 6% by weight or more of the total amount of oxcarbazepine.   61. The pharmaceutical composition of claim 60, wherein the amount of the large oxcarbazepine particle population is about 10% by weight or more of the total amount of oxcarbazepine.   62. The pharmaceutical composition of claim 61, wherein the amount of the large oxcarbazepine particle population is about 20% or more by weight of the total amount of oxcarbazepine.   58. The pharmaceutical composition of claim 57, wherein the small oxcarbazepine particle population is spray granulated.   64. The pharmaceutical composition of claim 63, wherein the small oxcarbazepine particle population is an oxcarbazepine particle population with d (0.5) less than about 6 microns.   65. The pharmaceutical composition according to any one of claims 63 and 64, wherein the amount of the small oxcarbazepine particle population is about 5% by weight or more of the total amount of oxcarbazepine.   66. The pharmaceutical composition of claim 65, wherein the amount of the small oxcarbazepine particle population is about 20% by weight or more of the total amount of oxcarbazepine.   68. The pharmaceutical composition of claim 66, wherein the amount of the small oxcarbazepine particle population is about 80% by weight or more of the total amount of oxcarbazepine.   68. The pharmaceutical composition according to any one of claims 57 to 67, wherein the oxcarbazepine particle size distribution in the spray granulated oxcarbazepine comprises a multimodal particle size distribution.   69. The pharmaceutical composition according to any one of claims 57 to 68, wherein the at least one excipient comprises hypromellose. A method of preparing a granular composition comprising at least two oxcarbazepine populations of different particle sizes, wherein at least one oxcarbazepine particle population is spray granulated,
a) preparing an oxcarbazepine comprising two or more oxcarbazepine particle populations having different particle size distributions;
b) preparing a dispersion of at least one oxcarbazepine particle population to form at least one oxcarbazepine dispersion;
c) spraying the oxcarbazepine dispersion onto one or more excipients to form at least one spray granulate; and
d) Mixing at least one spray-granulated oxcarbazepine particle population with the remaining non-spray-granulated oxcarbazepine particle population, and comprising an oxycarbazepine total amount in the composition Forming a Zepin mixture together.   The oxcarbazepine particles are characterized by a particle size distribution such that d (0.5) is less than 2 microns and more than 5% of the oxcarbazepine particles are retained on a 40 micron screen. Item 70. The method according to Item 70.   The oxcarbazepine particles are characterized by a particle size distribution such that d (0.5) is greater than 12 microns and more than 5% of the oxcarbazepine particles are retained on a 40 micron screen. 70. The method according to 70.   73. A method according to any one of claims 70 to 72, wherein the spray granulation is performed in a fluid bed apparatus.   Spraying the oxcarbazepine dispersion using a spray method selected from the group consisting of top spray, bottom spray, and tangential / powder spray. 74. A method according to any one of claims 70 to 73.   75. The method of claim 74, wherein the spraying method is an upward spraying method. e) mixing the granular composition with one or more excipients to form a tableting mixture;
76. A method according to any one of claims 70 to 75, further comprising the steps of f) pressing the tableting mixture into a tablet and optionally g) coating the tablet. . A method of preparing a granular composition comprising at least two oxcarbazepine populations of different particle sizes, wherein the at least one oxcarbazepine particle population is spray granulated,
a) preparing an oxcarbazepine comprising two or more oxcarbazepine particle populations having different particle size distributions;
b) preparing a dispersion of at least one oxcarbazepine particle population to form at least one oxcarbazepine dispersion;
c) Spraying the oxcarbazepine dispersion onto one or more excipients and at least one of the remaining oxcarbazepine populations, containing at least two populations A method comprising the step of forming an oxcarbazepine spray granulation. e) mixing the granular composition with one or more excipients to form a tableting mixture;
78. The method of claim 77, further comprising: f) pressing the tableting mixture into tablets to form tablets, and optionally g) pressing the tablets. In the dissolution profile in an aqueous buffer simulating the gastrointestinal environment,
a) About 35% or less of the total amount of oxcarbazepine elutes from the composition after 35 minutes of measurement in the dissolution apparatus,
b) About 50% to about 50% of the total amount of oxcarbazepine elutes from the composition after 50 minutes of measurement in the dissolution apparatus,
70. The pharmaceutical composition according to any one of claims 1 to 43 and 54 to 69, wherein about 30% to about 50% of the total amount of oxcarbazepine is eluted from the composition after 60 minutes of measurement in an elution device object.   80. The pharmaceutical composition of claim 79, wherein greater than 20% oxcarbazepine elutes from the composition in 35 minutes.   80. The pharmaceutical composition of claim 79, wherein 40% or more of the oxcarbazepine elutes from the composition in about 50 minutes. An aqueous buffer that mimics the gastrointestinal environment,
a) In the elution period from 0 to 20 minutes, 0.05N HCl and 2 g / l NaCl
b) In an elution period from 20 to 35 minutes, a pH 6 phosphate buffer containing 0.133% lecithin, and
82. The pharmaceutical composition according to any one of claims 79 to 81, comprising a pH 6 phosphate buffer containing 0.16% lecithin for an elution period from 35 to 65 minutes. In the dissolution profile in an aqueous buffer simulating the gastrointestinal environment,
a) About 35% or less of the total amount of oxcarbazepine elutes from the composition after 35 minutes of measurement in the dissolution apparatus,
b) About 50% to about 50% of the total amount of oxcarbazepine elutes from the composition after 50 minutes of measurement in the dissolution apparatus,
c) The pharmaceutical composition according to claim 5, wherein about 30% to about 50% of the total amount of oxcarbazepine is eluted from the composition after 60 minutes of measurement in the dissolution apparatus.   84. The pharmaceutical composition of claim 83, wherein greater than 20% oxcarbazepine elutes from the composition in 35 minutes.   84. The pharmaceutical composition of claim 83, wherein 40% or more of the oxcarbazepine elutes from the composition in about 50 minutes. An aqueous buffer that mimics the gastrointestinal environment,
a) In the elution period from 0 to 20 minutes, 0.05N HCl and 2 g / l NaCl
b) In an elution period from 20 to 35 minutes, a pH 6 phosphate buffer containing 0.133% lecithin, and
86. The pharmaceutical composition according to any one of claims 83 to 85, comprising a pH 6 phosphate buffer containing 0.16% lecithin for an elution period from 35 to 65 minutes.   The elution profile in a medium simulating the gastrointestinal environment, wherein a total amount of oxcarbazepine of 30% or more elutes within 60 minutes from the composition, any of claims 1 to 43, 53 to 69, and 79 to 86 A pharmaceutical composition according to claim 1.   88. The pharmaceutical composition according to claim 87, wherein the total amount of oxcarbazepine of 40% or more elutes from the composition within 60 minutes in an elution profile in a medium simulating the gastrointestinal environment.   The elution profile in a medium simulating the gastrointestinal environment, wherein 30% or more of the total amount of oxcarbazepine is eluted within 50 minutes from the composition, any of claims 1 to 43, 53 to 69, and 79 to 88 A pharmaceutical composition according to claim 1.   90. The pharmaceutical composition according to claim 89, wherein 30% or more of the total amount of oxcarbazepine is eluted within 35 minutes from the composition in an elution profile in a medium simulating the gastrointestinal environment.   The particle size distribution of oxcarbazepine has a d (0.5) value between about 13 microns and about 30 microns, and the dissolution rate of the composition in a device that mimics the gastrointestinal environment is 70. A pharmaceutical composition according to any one of claims 53 to 69, wherein the rate is such that about 30% to about 50% of the pin elutes from the composition within 50 minutes.   92. The pharmaceutical composition of claim 91, wherein about 40% or more of the oxcarbazepine elutes within 50 minutes from the composition.   70. The pharmaceutical composition according to any one of claims 27 to 43 and 53 to 69, wherein the disintegration time is less than about 30 minutes.   94. The pharmaceutical composition of claim 93, wherein the disintegration time is less than about 20 minutes.   95. The pharmaceutical composition of claim 94, wherein the disintegration time is less than about 15 minutes.   96. A method of treating a patient suffering from epileptic seizure, comprising a therapeutically effective amount of oxcarbazepine in a pharmaceutical composition according to any one of claims 1-43, 53-69, and 79-95, Administering to a patient in need thereof.   96. A method of treating a patient suffering from Parkinson's disease, wherein the therapeutically effective amount of oxcarbazepine in the pharmaceutical composition of any one of claims 1-43, 53-69, and 79-95, Administering to a patient in need thereof.   A pharmaceutical composition, method of preparation, composition or method of treatment according to any one of the preceding claims, wherein carbazepine is used instead of oxcarbazepine.

Images